Inositec AG

Swiss Biotech Association

Member

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Acthera Therapeutics AG

ACTHERA is a Swiss biotech company and is the result of over 10 years of academic research & development in the universities of Basel, Fribourg and Texas Dallas (USA). The therapeutic platform is based on Hard-Shelled Liposomes (HSLs) that can contain a broad variety of therapeutically active ingredients. ACTHERA’s unique and highly innovative release mechanism will allow the release of active ingredients at therapeutic sites, thus revealing an extraordinarily wide field of applications to transform numerous therapeutic areas.
4052 Basel

Member

Perseo pharma AG

Perseo pharma: best-in-class enzyme therapeutics Perseo pharma is a preclinical-stage biotech start-up developing best-in-class enzyme therapeutics based on an innovative proprietary nanotechnology platform.
4057 Basel

Member

OM Pharma Ltd

OM Pharma is a global Geneva-based Biotech company. It is a leader in the prevention of recurrent respiratory and urinary tract infections and is also active in the treatment of vascular diseases. It operates worldwide through a strong network of international partners and continues to invest into R&D to develop microbial derived immunotherapeutic products addressing acute and chronic immunological disorders resulting from infections and inflammation. OM Pharma is operating to highest Good Manufacturing Practice (GMP) standards which rely on a high level of Biotech competencies and experienced teams. The company strives to help patients around the world to live better lives by allowing access to a better management of infectious diseases and immunological imbalances.
1217 Meyrin

Member